Upload
others
View
1
Download
0
Embed Size (px)
Citation preview
PROVAXSYour partner for innovation in animal health
INNOVATION THROUGH PARTNERSHIP AND COLLABORATION
54
Discover 3 reasons why PROVAXS can become the preferred
academic partner to support your innovation-projects in animal
health.
YOUR PARTNER FOR INNOVATION
IN ANIMAL HEALTHTHE EXPERTISE, KNOWLEDGE AND KNOW HOW OF OUR SCIENTISTS
AN ENTREPRENEURIAL ORGANIZATION OF SCIENTISTS AND EXPERIENCED TECH TRANSFER PROFESSIONALS
ACCESS TO PROOF OF CONCEPT FUNDING
PROVAXS
76
THE EXPERTISE, KNOWLEDGE AND KNOW HOW of our scientists
PROVAXS offers access to a network of laboratories at Ghent
University with a focus on infectious diseases and immunity that
unite their expertise for the development of innovative vaccines,
targeted therapeutics, feed additives and diagnostics.
We offer in depth academic expertise and research capacity on
selected animal pathogens and the interaction with their host.
A network of leading professors, each with in depth expertise in
one of the following animal diseases:
• Actinobacillus
pleuropneumoniae
• Brachyspira
• Chlamydia trachomatis
• Escherichia coli F4/K88
• Escherichia coli F18
• Helicobacter
• Mycoplasma
hyopneumoniae
• Salmonella
• Chlamydia suis
• PCV2
• PPRSV
• PRV
• SIV
• Porcien rotavirus
• Ascaris suum
• Toxoplasma gondii
• Trichuris suis
BACTERIA
VIRUS
PARASITE
• Escherichia coli (APEC)
• Campylobacter
• Chlamydia psittaci
• Clostridium perfringens
• Ornithobacterium
rhinotracheale
• Salmonella
• Escherichia coli
(EHEC)
• Cooperia oncophora
• Giardia duodenalis
• Fasciola hepatica
• Ostertagia ostertagi
• Psoroptes ovis
• Escherichia coli
(EHEC)
• Toxoplasma gondii
• Giardia duodenalis
• Mycotoxins in vitro
and in vivo
(pigs and poultry)
98
ACADEMIC AND REGULATORY EXPERTISE
• Know how of professors and academic scientists who perform
breakthrough research in their field of expertise
• Tailor-made study design and protocol
• In depth data evaluation and interpretation of results by
academic experts
• Ready-to-use results and reports
• Experience in vaccine development
• Contribution to WAAVP and VICH guidelines
• Member of EMA advisory board
VARIOUS CHALLENGE MODELS AND IN VITRO MODELS
• Efficacy studies according to WAAVP and VICH guidelines
(including early evaluation of efficacy, comparative studies
and studies for registration purposes)
• Use of highly characterised challenge strains in reliable and
reproducible models
• Classical infection and seeder-models
• Pathogenesis and vaccination-challenge studies
• Various in vitro models to quantify virus replication and/
or determine cell tropism e.g. polarized nasal explants,
macrophages/monocytes, cardiomyocytes
• in vitro: MIC, transwell insert model, cell invasion test,…
• in vitro/in vivo: intestinal loop model (pig), caecal loop model
(chicken)
• A panel of in vitro and in vivo tests to determine innate (NK cells,
macrophages, neutrophils), humoral (antibodies, antibody
secreting cells) and cellular (lymphocyte identification,
cytokine responses, dendritic cells) immune responses
1110
EXPERIENCED BSL2/3 LABORATORIES
AND ANIMAL FACILITIES
• Sample analysis in a broad diagnostic context (bacteriological,
virological, parasitological )
• Quantification of pathogenic load upon infection and/or
vaccination-challenge (e.g. organs, excretions, blood)
• Quantification of serological responses to vaccination and
infection
• Necropsy and histopathology
• Genetic sequencing and analysis
FIELD STUDIES
• Networking with farmers and farm organisations
• Efficacy studies under field conditions combined with
monitoring of effects on the productivity of the animals
• Collection of recent local field isolates
OUR FOCUS IS ON ANIMAL HEALTH
BUT SOME TECHNOLOGIES
AND KNOW HOW CAN BE USED FOR
OR TRANSLATED TO APPLICATIONS
IN HUMAN MEDICINE
13
AN ENTREPRENEURIAL ORGANIZATION OF SCIENTISTS AND EXPERIENCED TECH TRANSFER PROFESSIONALS
WITH PROVAXS WE COMBINE
• The insight and know how of professors and academic
scientists who perform breakthrough research in their field of
expertise.
• High quality management of the collaboration with our
partners by an experienced team of tech transfer professionals
with special attention to swift contract negotiations,
confidentiality of results and intellectual property and follow up
of milestones and deliverables.
We are open for all kinds of collaboration with our partners:
• PhD research with industrial applications: evaluate how results
of early discovery projects can fit in your R&D-activities
• R&D-collaboration: partner with our academic experts and
research teams to validate your ideas or to complement your
own R&D-capacity
• Outlicensing/co-development: accelerate your product develop-
ment and build on validated research results, proof of concept
data and intellectual property with a strong academic basis
• Services: use our validated assays (in vitro, ex vivo, in situ) and
animal models in your development program or post marketing
studies
1514
BUSINESS DEVELOPMENT
MANAGEMENT
& BUSINESS DEVELOPER
Sven Arnouts
ADMINISTRATIVE
ASSISTANT
Debbie Colman
INTELLECTUAL
PROPERTY
Nathalie Brutsaert
LEGAL Bernadette Tuerlinckx
VC & CORPORATE
FINANCE
Patrick Dhaese
FUNDING Margo Baele (EU),
Karen Curé (IWT),
Ingrid Merchiers (IOF)
RESEARCH AND DEVELOPMENT
BACTERIOLOGY Freddy Haesebrouck,
Frank Pasmans,
Filip Van Immerseel
PARASITOLOGY Edwin Claerebout,
Peter Geldhof
VIROLOGY Hans Nauwynck,
Kristien Van Reeth
IMMUNOLOGY Eric Cox,
Herman Favoreel,
Daisy Vanrompay
PATHOLOGY Richard Ducatelle
FORMULATION
& DELIVERY
Dieter Deforce,
Stefaan De Smedt EXP
ERTI
SE
16 17
We have access to funding bodies like IWT (Flanders), FWO and the
Federal Public Service Health Food Chain Safety and Environment
(Belgium), Horizon2020 (EU).
Next to that Ghent University offers its researchers and their part-
ners funding for exclusive use at crucial stages of the development
track of innovation-oriented projects.
Depending on the stage of maturation four types of projects can be
applied for.
CONCEPTT
• Exploration
• 25.000 – 50.000EURO
• 1 year
STARTT
• Identification/initiation
• 50.000 - 100.000EURO
• 1-2 year
ADVANCED
• Licence/spin-off or preparation of StepStone
• Max 250.000EURO
• Max 2 year
• Cofinancing industrial partner is a strong asset
STEPSTONE
• Close to technology transfer
• Max 650.000EURO
• Max 3 year
• Cofinancing industrial partner obligatory (license)
These projects can thus be used to mature research results and novel
technologies towards transfer to industrial partners or to create new
start up companies:
• Generate proof of concept data during the priority year of a
patent application to support the claims
• Generate additional data to validate a target or a technology
and fill the gaps identified by an industrial partner interested
in licensing
• Evaluate industrial proof of concept and/or the market
potential of a new technology in preparation of or as the first
step of an academic-industrial partnership
ACCESS TO PROOF OF CONCEPT FUNDING
RESEARCH Innovative research results
IOF StarTT
IOF ConcepTT
IOF Advanced
IOF Stepstone
License negotiations
Spin-off incubation
CONCEPT
DEFINITION
TECHNICAL
PROOF OF
CONCEPT
INDUSTRIAL
PROOF OF
CONCEPT
VALORISATION
1918
At Ghent University we strongly believe that increased collaboration with
our industrial partners can lead to cross-fostering and will increase in-
novation.
More than 6.500 researchers covering more than 80 nationalities are in-
volved in basic research, working at the Ghent University Association,
the Ghent University Hospital, or at one of the strategic research insti-
tutes like VIB (Flemish Institute for Biotechnology) or imec (nano-elec-
tronics research center and digital research and incubation center – for-
merly iMinds).
Together they realize an R&D investment of more than 250 million euros,
of which more than 25% was financed by industry, which illustrates the
intensive collaboration with companies worldwide.
The city of Ghent houses the largest student population of Belgium with
about 65.000 higher education students including more than 3.600 PhD
students. Ghent University has 30.000 students, 10.000 of which are
specializing in medicine and life sciences. The Ghent region is also an
important economic hub within one hour drive from the capital of the
European Union.
Science parks are available in Ghent (TechLane) and Ostend (Green-
bridge) for research oriented companies that want office space in the vi-
cinity of the university association, either to facilitate collaboration and to
get access to the available talent pool, or to operate close to like-minded
companies. Within the science parks multiple incubators are available
to early stage spin-offs and start-ups. They provide a full set of office
and business services, and can arrange for access to the university’s
research infrastructure and pilot plants. The Incubation and Innovation
Center (IIC UGent) is the general incubator. Domain specific incubators
include: Greenbridge (Ostend, blue energy), VIB Bio Incubator
(Ghent, biotech), Bio-Accelerator (Ghent, biotech), and iMinds iCUBES
(Ghent, ICT).
In total some 40 biotech/life science companies are located in Ghent or
the Ghent area, covering the health, industrial/environmental and agri-
cultural/food sectors.
THE GHENT INNOVATION HUB
21
Your collaboration with PROVAXS will bring you into contact with
our scientists, their expertise and the innovative ideas they are
developing towards industrial applications.
Ghent University has created a number of business develop–
ment centers that group complementary research departments
by application and area or domain of expertise. Each center is
respon sible for technology transfer within its area of compe-
tence.
We can bring you into contact with those BD-centers that offer
expertise and technologies that are complementary to your pro-
ject, thus generating new opportunities and leads for innovation.
FROM COLLABORATION TO THE IDENTIFICATION OF NEW OPPORTUNITIES AND LEADS
2322
Technology transfer at Ghent University wants to facilitate the commercial
application of promising technologies developed within the Ghent Univer-
sity Association. Key technology transfer activities include industrial col-
laboration programs, IP licensing and spin-off creation. For its liaison
with industry , UGent uses a network of specialized business development
centres backed by a Central Technology Transfer Office.
ENERGY& CLEANTECH
MATERIALS ELECTRONICS & PHOTONICS
ICT MEDICAL PHARMA BIOTECH FOOD
CENTRAL TECHNOLOGY TRANSFER OFFICE
DuraBuildmaterials
CONTACT
Sven Arnouts, PhD RTTPBusiness Development Manager PROVAXS - University of GhentSalisburylaan 133, 9820 Merelbeke (BE)T +32 9 264 73 33M +32 495 707 334E [email protected]